(0.31%) 5 115.94 points
(0.30%) 38 355 points
(0.37%) 15 988 points
(-0.95%) $83.05
(5.36%) $2.03
(0.33%) $2 355.00
(0.48%) $27.67
(4.15%) $960.35
(-0.27%) $0.932
(-0.45%) $10.97
(-0.58%) $0.796
(1.63%) $93.37
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.53%
Live Chart Being Loaded With Signals
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States...
Stats | |
---|---|
本日の出来高 | 4 815.00 |
平均出来高 | 26 439.00 |
時価総額 | 70.12M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $-2.74 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.960 |
ATR14 | $0.162 (1.27%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Mchutchison John G | Sell | 1 206 | Common Stock |
2024-03-29 | Bjorkquist Jeanette M | Buy | 850 | Common Stock |
2024-04-01 | Bjorkquist Jeanette M | Sell | 114 | Common Stock |
2024-03-29 | Bjorkquist Jeanette M | Buy | 1 550 | Stock Option (right to buy) |
2024-03-29 | White Nicole S | Buy | 17 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
65.38 |
Last 96 transactions |
Buy: 4 380 980 | Sell: 646 377 |
Assembly Biosciences Inc 相関
10 最も負の相関 | |
---|---|
DNUT | -0.904 |
NRDS | -0.897 |
DSPG | -0.897 |
EPZM | -0.893 |
XOG | -0.892 |
SGEN | -0.889 |
CNCE | -0.885 |
TYHT | -0.881 |
BTBD | -0.875 |
STAY | -0.874 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Assembly Biosciences Inc 財務諸表
Annual | 2023 |
収益: | $7.16M |
総利益: | $6.71M (93.72 %) |
EPS: | $-13.38 |
FY | 2023 |
収益: | $7.16M |
総利益: | $6.71M (93.72 %) |
EPS: | $-13.38 |
FY | 2022 |
収益: | $0 |
総利益: | $-498 000 (0.00 %) |
EPS: | $-22.82 |
FY | 2021 |
収益: | $6.25M |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.67 |
Financial Reports:
No articles found.
Assembly Biosciences Inc
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。